Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Keeping Track: Shionogi, Fresenius Kabi Join July Approval Parade; Busy August Expected

Keeping Track Feature image

Related Content

Keeping Track: Ilumya, Adcetris Approved; Xtandi Priority Reviewed; Azedra Goal Date Extended

Mar 24 2018

Master Protocols Are Both Welcome And Inevitable – US FDA's Woodcock

Jul 07 2017

US FDA's Gottlieb Touts 'Seamless' Clinical Trials, Worries About Second-To-Market Products

Jul 26 2018

FDA's Gottlieb Pushing 'Seamless' Clinical Trials For Faster Development

Sep 12 2017

Breakthrough Status Arrives Late In Development Of Yervoy+Opdivo, Enfortumab Vedotin And Pedmark

Mar 30 2018

Keeping Track: We're Back!

Jan 19 2018

Keeping Track: Thumbs Up For Doptelet And Palynziq, Thumbs Down For Methylene Blue MMX And Meloxicam

May 29 2018

Dova’s Doptelet Gets First-To-Market Edge In Thrombocytopenia, Ahead Of Shionogi

May 22 2018

Daiichi's Phase III Quizartinib Data Pave Way In Niche AML Market

Jun 18 2018

Nektar's NKTR-214 IO Deal With Bristol Looks Even Sweeter With More Data

Mar 03 2018

Keeping Track: Bristol Tests US FDA’s TMB Tolerance, Celltrion Resubmits Herceptin Biosimilar, Nocdurna Approved At Last

Jun 24 2018

Related Companies

Shionogi & Co. Ltd.

Fresenius SE & Co. KGaA

Progenics Pharmaceuticals, Inc.

Merck & Co., Inc.

Daiichi Sankyo Co., Ltd.

Dova Pharmaceuticals, Inc.

General Electric

Cassava Sciences, Inc.

INSYS Therapeutics, Inc.

Charleston Laboratories, Inc.

Evolus, Inc.

Eisai Co., Ltd.

Additional Topics

United States Drug Review Regulation BioPharmaceutical

More from Product Reviews

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window